MIT-001

MitoImmune Therapeutics · Phase 2 active Small molecule

At a glance

Generic name	MIT-001
Sponsor	MitoImmune Therapeutics
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (PHASE2)
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (PHASE2)
Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MIT-001 CI brief — competitive landscape report
MIT-001 updates RSS · CI watch RSS
MitoImmune Therapeutics portfolio CI